Novartis Venture Fund

Boston, Massachusetts
Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capitalefficiency in the program. We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100'000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates.
Founded:1996
Firm Location:Boston, Massachusetts • Cambridge, Massachusetts • Basel, Switzerland • Zurich, Switzerland
Novartis Venture Fund Team
Photo of Elena Battistello, Analyst at Novartis Venture Fund
Elena Battistello
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Zurich (Switzerland), Investors in Europe
Investors in BioTech (Series A), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Seed)
Photo of Laura Brass, Managing Director at Novartis Venture Fund
Laura Brass
Novartis Venture Fund·Managing Director
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Cambridge (MA)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Boston / New England (Other Lists)
Photo of Adam Cotton, Associate at Novartis Venture Fund
Adam Cotton
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Cambridge (MA)
Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Boston / New England (Other Lists)
Photo of Bart Dzikowski, Managing Director at Novartis Venture Fund
Bart Dzikowski
Novartis Venture Fund·Managing Director
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Europe, Investors in Basel (Switzerland)
Investors in BioTech (Series A), Investors in BioTech (Seed)
Photo of Mathias Frederiksen, Principal at Novartis Venture Fund
Mathias Frederiksen
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Europe, Investors in Basel (Switzerland)
Investors in BioTech (Series A), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed)
Photo of Anja Konig, Managing Director at Novartis Venture Fund
Anja Konig
Novartis Venture Fund·Managing Director
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Basel (Switzerland)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A)
Photo of Michelle Ma, Analyst at Novartis Venture Fund
Michelle Ma
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Boston (MA)
Investors in BioTech (Series A), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Boston / New England (Other Lists)
Photo of Florian Müllershausen, Managing Director at Novartis Venture Fund
Florian Müllershausen
Novartis Venture Fund·Managing Director
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Basel (Switzerland)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A)
Photo of Aaron Nelson, Managing Director at Novartis Venture Fund
Aaron Nelson
Novartis Venture Fund·Managing Director
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Cambridge (MA)
Investors in Chemicals (Seed), Investors in Therapeutics (Series A), Investors in BioTech (Series A), Investors in Chemicals (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Chemicals (Seed), Investors in BioTech (Series A), Investors in Chemicals (Series A), Investors in Boston / New England (Other Lists), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A)
Photo of Michal Silverberg, Managing Director at Novartis Venture Fund
Michal Silverberg
Novartis Venture Fund·Managing Director
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Boston (MA)
Investors in BioTech (Series A), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Boston / New England (Other Lists)
Photo of Beat Steffen, Managing Director at Novartis Venture Fund
Beat Steffen
Novartis Venture Fund·Managing Director
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Basel (Switzerland)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A)
Photo of Marianne Uteng, Managing Director at Novartis Venture Fund
Marianne Uteng
Novartis Venture Fund·Managing Director
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Basel (Switzerland), Investors in Europe
Investors in BioTech (Series A), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed)